MXD3 and melanoma: In addition, we found that lower expression levels of MXD3 were associated with clinical benefits of ICB therapy (PD-1 or PD-L1) in melanomas, glioblastomas, and kidney cancer and hence exhibited prolonged survival periods compared to cohorts with high MXD3 expression levels (Fig. 7C, upper panel).